This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Bipolar Disorder Drugs and Treatment Market

Market Insights on Bipolar Disorder Drugs and Treatment covering sales outlook, demand forecast & up-to-date key trends

Bipolar Disorder Drugs and Treatment Market By Drug Class (Mood Stabilizers, Anticonvulsants, Anti-psychotic Drugs, Anti-Depressant Drugs, and Anti-anxiety Drugs) & Region - Forecast 2022 - 2032

Bipolar Disorder Drugs and Treatment Market Outlook (2022-2032)

[350 Pages Report] The global bipolar disorder drugs and treatment market is forecasted to grow at a moderate CAGR of 3%, reaching nearly US$ 8.1 Bn by 2032 from US$ 5.7 Bn in 2021.

“Changing perspective about the importance of mental health treatments is anticipated to raise the sale of over the counter meds for bipolar disorder.”

As per the historical records, around 50 million people in the world suffer from some level of bipolar disorder and undergo some kind of depression in their early 20s.

According to the Global Burden of Disease report, the prevalence of bipolar disorder ranges from 0.3% to 1.2% among different regions. In recent years there has awareness about the disorder is growing shifting the perspective for it as a mental ailment creating a surge in the sale of natural bipolar medication.

With the changing perspective about mental health, the demand for natural bipolar meds or drugs is anticipated to grow by the patients suffering from such disease. A similar category of drugs, commonly known as bipolar depression treatment medication, is increasingly available in all parts of the world.

Attributes

Details

Bipolar Disorder Drugs and Treatment Market CAGR (2022-2032)

3%

Bipolar Disorder Drugs and Treatment Market (2027)

US$ 7 Bn

Bipolar Disorder Drugs and Treatment Market Attraction

Support from the government organizations to increase awareness about the bipolar disorder is the major factor driving the bipolar drugs market.

Customize this Report

Let us know your requirement to get
100% FREE customization

What is the Covid-19 Impact on Bipolar Disorder Drugs and Treatment Market?

The market for bipolar disorder drugs and treatment was mildly hit by the Covid-19 pandemic restrictions. As there were widespread positive cases of patients infected by the novel Corona Virus, most of the resources and professionals of the healthcare sector were diverted towards the management of the Covid-19 menace.

Particularly the demand for medication for bipolar from the hospital and healthcare institutions dropped significantly. Surprisingly enough, the number of patients diagnosed with bipolar disorders increased significantly during the worldwide shutdown of the free movement of people.

This fact is hypothesized from the information of the increase in the volume of over the counter medicine for bipolar available during the pandemic times.

However, the market growth for prescribed drugs continued through the increase in bipolar meds online availability on e-commerce sites.

As the healthcare sector was kept as the most prioritized business activity, the drugs market recovered from the jolt of the pandemic within a few days. There were also some remarkable developments in the field of herbal medicine for bipolar disorder that has emerged as a successful niche for the bipolar disorder drugs and treatment market.

What is the Present Dynamics of the Global Bipolar Disorder Drugs and Treatment Market?

Bipolar disorders have been recognized as the 6th largest contributor in the total disabled person in the world by World Health Organizations or WHO. To mitigate the serious consequences, modern medical science has developed therapeutic drugs for its treatment that is available as bipolar over the counter meds in the drug stores.

Previously the consciousness and awareness about the remedial measures for any type of mental disorder were below the level resulting in less demand for good medicine for bipolar disorder produced by the pharmaceutical companies. However, in recent days with the growth in digital media, the acceptance of methods for treatment of bipolar is reflected in the huge growth in sales of over the counter meds for bipolar.

There is also some old age natural medication for bipolar disorder that is being actively researched and developed by pharmaceutical companies to augment their customer base. Many market players have succeeded in creating brand values by supplying mood stabilizers online to customers.

What are the Challenges Faced by Players in the Bipolar Disorder Drugs and Treatment Market?

The lithium (Li) element used in the production of anti mania drugs can cause anorexia if taken by an overdose. Also, the prolonged use of lithium can damage the effects of vasopressin hormone that can result in diabetes insipid, as sighted by many reports. This tact can hinder the wider adaptability of bipolar over the counter meds for disorder treatment as well.

As the typical age group for the emergence of any symptom of bipolar disorder is around 20 to 25 years, so it often gets neglected by the parents. This delays the tremendous procedure for bipolar disorders and reduces the effectiveness of natural bipolar meds, and hampers the value of the drug in the Market. Over the years, there are also a lot of generic medicines coming into the market in competition with well-established market chains of OTC mood stabilizer medications. 

Addiction of the body to such types of drugs is another major concern for the use of such types of drugs by the patients. There is also very less number of anticonvulsant drugs approved for use as bipolar disorder medication over the counter that can hamper the rapid growth of the global market.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Comparative View of Adjacent Bipolar Disorder Drugs and Treatment Market

Attributes

Bipolar Disorder Drugs and Treatment Market

Anti-mania Drugs Market

Behavioral Health Market

CAGR (2022 - 2032)

3%

10.2%

7.6%

Market Value (2027)

US$ 7 Bn

US$ 22 Bn

US$  42.3 Bn

Growth Factor

Growing Awareness about the effectiveness of drugs in treating bipolar disorders have increased its demand.

By the support of government and international organizations mental disorder drugs are getting affordable and available in the market

Alcohol overuse disorders are getting more common in recent times and requiring most of the behavioral health market drugs.

Opportunity

In Asia Pacific region the bipolar disorder cases are growing with the rapid urbanization with a great opportunity for market players.

Innovative drugs discovered in the field of psychiatric disease have come up with new effective medicines for mental health.  

Emergency mental health services require sedatives as a precaution to deteriorating condition of patients growing the demand for it.

Key Trends

With the rationalization of drug regulations the sale of bipolar medicine on online platforms have increased.

Increasing number of clinical tests is rising the count of mental disorder cases growing the demand for such drugs.

With the starting of home based treatment services for behavioral health patients the sale of drugs on online platforms have increased.

National Institute of Mental Health (NIMH) provides data for the number of people in USA developing bipolar disorder symptoms at approximately 10 million. By the support of government initiatives and dissemination of knowledge about the mental condition of such patients there has been an encouraging environment for their treatment through good medicine for bipolar disorder.

These drugs are also classified on the basis of mechanism they adopt to get into action. Selective serotonin reuptake inhibitor and serotonin norepinephrine reuptake inhibitors are the most prominent segments of liquid bipolar medication used for the bipolar disorder remedies.

The other segments in this category include tricyclic antidepressants, Menominee oxidase inhibitors, benzodiazepines, and beta blockers.

What is the Growth Outlook for the Bipolar Disorder Drugs and Treatment Market According to Different Class of Drugs?

The antipsychotic drugs are suitable to be used in combination therapy along with SSRI. Most healthcare professionals opt for antipsychotics drugs as it demonstrates better results than the other types of over the counter medicine for bipolar available in the market.

This segment is expected to contribute the major share of the revenue generated by the global bipolar disorder drugs and treatment market. It is also expected to grow at a higher CAGR of 2.8% than the other segments of the market over the forecast period. The antipsychotics drugs segment is estimated to be valued at US$ 3 Bn in the year 2027.

Anticonvulsant drugs are getting more adopted these days by physicians establishing a CAGR of 3.7% during the forecast years.

Names of some of the anticonvulsant drugs available in the form of best over the counter medicine for bipolar treatment include carbamazepine or Equetro, divalproex sodium or Depakote, lamotrigine or Lamictal, topiramate or Topamax and valproic acid, which is otherwise known as Depakene.

All of these anticonvulsant drugs currently account for 22% of the total global bipolar treatment market drugs and are expected to record a CAGR of 3.7% together, as mentioned before.

Mood stabilizer drugs help in controlling the swings in manic and depressive phases experienced by the patient by restoring the neurochemical balance.

A major percentage of customers for the mood stabilizer medications over the counter is present in developed economies such as the USA, Canada, Japan, and European countries of Spain, France, Germany, UK and Italy, commonly recognized as 8MM in the global bipolar disorder drugs and treatment market.

These regional markets together account for a market size of nearly US$ 874 Mn in 2021 and are projected to reach a valuation of US$ 1 bn by the end of the year 2027.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

What is the Performance of the Bipolar Disorder Drugs and Treatment Market?

The number of bipolar disorder cases in the North American region has been observed to be increasing day by day. The increase in disruption of daily lifestyle like insufficient sleep, wrong food habits or substance abuse and higher stress level in the youngster is the reason for the increasing sale of mood stabilizer medications over the counter, particularly in the USA.

On the record, North America accounted for more than 60% of the total revenue generated by the bipolar disorder drugs market globally. North America is predicted to retain its leading position during the forecast years, reaching a valuation of US$ 2.6 Bn in the year 2022.

Asia Pacific region is the significant region for the global bipolar disorder drugs and treatment market in terms of the highest growth rate in recent times.

A recent report published by World Health Organizations (WHO) ranked China and India as the top regions with patients diagnosed with anxieties, schizophrenia and bipolar disorders that will increase the sale of natural medications for bipolar disorder.

China, with a robust pharmaceutical manufacturing industry, is predicted to reach a valuation of more than US$ 500 Mn by the end of the year 2027. China is predicted to record a robust CAGR of 4.5% in the bipolar disorder drugs and treatment market over the forecast years.

Europe is estimated to grow at a CAGR less than the global average at 2.5% during the forecast period of 2022 to 2032. Strong policies to regulate the sale of over the counter medication for bipolar disorder is expected to limit the growth of bipolar disorder drugs and the treatment market in this region.

What are the Competitive Opportunities for the Global Bipolar Disorder Drugs and Treatment Market?

The main strategies adopted by the market players include the development of new drugs for bipolar disorder over the counter medication by investing in research and development (R&D) activities. Acquiring approvals for such over the counter medications is the most important step in gaining recognition for the newly developed medicines.

Expanding business activities by acquisition and merger of the locally established manufacturers supplying mood stabilizer medications over the counter in any area.

What are the Recent Developments in the Field of Bipolar Disorder Drugs and Treatment Market?

  • For the treatment of bipolar I disorder among adults, Alkermes PLC developed a treatment drug by the name of LYBALVITM that is a combination of olanzapine and samidorphan. It received the approval of the US Food and Drug Administration (FDA) in June 2021, which will make it available as an over the counter medicine for bipolar treatment. 
  • The University of Illinois, which is present in the state of Chicago, launched a cell phone app by the name of BiAffect in 2018 that helps in tracking the manic disorder and depressive mood for the patients having bipolar disorder.
  • Allergan PLC and Gedeon Richter PLC expanded the use of Vraylar, also known as cariprazine used in the treatment of the depressive condition in adults suffering from bipolar disorder after getting approval from the US Food and Drug Administration (FDA) by May 2019.

Key Players

  • AbbVie Inc.
  • Glaxo SmithKline (GSK)
  • Eli, Lily and Company
  • Janssen Pharmaceuticals
  • Johnson & Johnson
  • Astellas Pharma Inc
  • Bristol Myers Squibb
  • Gedeon Richter PLC.
  • H. Lundbeck A/S
  • Pfizer Inc.
  • Novartis AG
  • Otsuka Holdings Co. Ltd
  • Validus Pharmaceuticals LLC.

Key Segments

By Drug Class:

  • Mood Stabilizers
  • Anticonvulsants
  • Antipsychotic Drugs
  • Antidepressant Drugs
  • Anti-anxiety Drugs

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa (MEA)

Frequently Asked Questions

The bipolar disorder drugs and treatment market is estimated to record a CAGR of 3% during the forecast period.

The bipolar disorder drugs and treatment market is predicted to be valued at US$ 8.1 by the end of forecasted period of 2032.

The global bipolar disorder drugs and treatment market was valued at US$ 5.7 Bn in 2021.

North America accounts for the largest revenue share accounting more than 60% of the global bipolar disorder drugs and treatment market.

Asia Pacific region is predicted to witness the highest growth rate in the human bipolar disorder drugs and treatment market.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity 

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Product Life Cycle Analysis

    3.5. Investment Feasibility Matrix

    3.6. PESTLE and Porter’s Analysis

    3.7. Regulatory Landscape

        3.7.1. By Key Regions

        3.7.2. By Key Countries

    3.8. Regional Parent Market Outlook

4. Global Bipolar Disorder Drugs and Treatment Market Analysis 2017-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Bipolar Disorder Drugs and Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Class, 2017-2021

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Class, 2022-2032

        5.3.1. Mood Stabilizers

        5.3.2. Anti-convulsants

        5.3.3. Anti-psychotic Drugs

        5.3.4. Anti-depressant Drugs

        5.3.5. Anti-anxiety Drugs

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2017-2021

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2022-2032

6. Global Bipolar Disorder Drugs and Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Region

    6.1. Introduction

    6.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021

    6.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

        6.3.1. North America

        6.3.2. Latin America

        6.3.3. Europe

        6.3.4. Asia Pacific

        6.3.5. Middle East and Africa

    6.4. Market Attractiveness Analysis By Region

7. North America Bipolar Disorder Drugs and Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    7.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    7.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        7.2.1. By Country

            7.2.1.1. U.S.

            7.2.1.2. Canada

        7.2.2. By Drug Class

    7.3. Market Attractiveness Analysis

        7.3.1. By Country

        7.3.2. By Drug Class

    7.4. Key Takeaways

8. Latin America Bipolar Disorder Drugs and Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        8.2.1. By Country

            8.2.1.1. Brazil

            8.2.1.2. Mexico

            8.2.1.3. Rest of Latin America

        8.2.2. By Drug Class

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Drug Class

    8.4. Key Takeaways

9. Europe Bipolar Disorder Drugs and Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        9.2.1. By Country

            9.2.1.1. Germany

            9.2.1.2. Italy

            9.2.1.3. France

            9.2.1.4. U.K.

            9.2.1.5. Russia

            9.2.1.6. BENELUX

            9.2.1.7. Rest of Europe

        9.2.2. By Drug Class

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

    9.4. Key Takeaways

10. Asia Pacific Bipolar Disorder Drugs and Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. China

            10.2.1.2. Japan

            10.2.1.3. South Korea

            10.2.1.4. Rest of Asia Pacific

        10.2.2. By Drug Class

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

    10.4. Key Takeaways

11. Middle East and Africa Bipolar Disorder Drugs and Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. GCC Countries

            11.2.1.2. South Africa

            11.2.1.3. Turkey

            11.2.1.4. Rest of Middle East and Africa

        11.2.2. By Drug Class

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

    11.4. Key Takeaways

12. Key Countries Bipolar Disorder Drugs and Treatment Market Analysis

    12.1. U.S.

        12.1.1. Pricing Analysis

        12.1.2. Market Share Analysis, 2021

            12.1.2.1. By Drug Class

    12.2. Canada

        12.2.1. Pricing Analysis

        12.2.2. Market Share Analysis, 2021

            12.2.2.1. By Drug Class

    12.3. Brazil

        12.3.1. Pricing Analysis

        12.3.2. Market Share Analysis, 2021

            12.3.2.1. By Drug Class

    12.4. Mexico

        12.4.1. Pricing Analysis

        12.4.2. Market Share Analysis, 2021

            12.4.2.1. By Drug Class

    12.5. Germany

        12.5.1. Pricing Analysis

        12.5.2. Market Share Analysis, 2021

            12.5.2.1. By Drug Class

    12.6. Italy

        12.6.1. Pricing Analysis

        12.6.2. Market Share Analysis, 2021

            12.6.2.1. By Drug Class

    12.7. France

        12.7.1. Pricing Analysis

        12.7.2. Market Share Analysis, 2021

            12.7.2.1. By Drug Class

    12.8. U.K.

        12.8.1. Pricing Analysis

        12.8.2. Market Share Analysis, 2021

            12.8.2.1. By Drug Class

    12.9. Russia

        12.9.1. Pricing Analysis

        12.9.2. Market Share Analysis, 2021

            12.9.2.1. By Drug Class

    12.10. BENELUX

        12.10.1. Pricing Analysis

        12.10.2. Market Share Analysis, 2021

            12.10.2.1. By Drug Class

    12.11. China

        12.11.1. Pricing Analysis

        12.11.2. Market Share Analysis, 2021

            12.11.2.1. By Drug Class

    12.12. Japan

        12.12.1. Pricing Analysis

        12.12.2. Market Share Analysis, 2021

            12.12.2.1. By Drug Class

    12.13. South Korea

        12.13.1. Pricing Analysis

        12.13.2. Market Share Analysis, 2021

            12.13.2.1. By Drug Class

    12.14. GCC Countries

        12.14.1. Pricing Analysis

        12.14.2. Market Share Analysis, 2021

            12.14.2.1. By Drug Class

    12.15. South Africa

        12.15.1. Pricing Analysis

        12.15.2. Market Share Analysis, 2021

            12.15.2.1. By Drug Class

    12.16. Turkey

        12.16.1. Pricing Analysis

        12.16.2. Market Share Analysis, 2021

            12.16.2.1. By Drug Class

13. Market Structure Analysis

    13.1. Competition Dashboard

    13.2. Competition Benchmarking

    13.3. Market Share Analysis of Top Players

        13.3.1. By Regional

        13.3.2. By Drug Class

14. Competition Analysis

    14.1. Competition Deep Dive

        14.1.1. AbbVie Inc.

            14.1.1.1. Overview

            14.1.1.2. Product Portfolio

            14.1.1.3. Profitability by Market Segments

            14.1.1.4. Sales Footprint

            14.1.1.5. Strategy Overview

                14.1.1.5.1. Marketing Strategy

        14.1.2. Glaxo SmithKline (GSK)

            14.1.2.1. Overview

            14.1.2.2. Product Portfolio

            14.1.2.3. Profitability by Market Segments

            14.1.2.4. Sales Footprint

            14.1.2.5. Strategy Overview

                14.1.2.5.1. Marketing Strategy

        14.1.3. Eli Lilly and company

            14.1.3.1. Overview

            14.1.3.2. Product Portfolio

            14.1.3.3. Profitability by Market Segments

            14.1.3.4. Sales Footprint

            14.1.3.5. Strategy Overview

                14.1.3.5.1. Marketing Strategy

        14.1.4. Janssen Pharmaceuticals

            14.1.4.1. Overview

            14.1.4.2. Product Portfolio

            14.1.4.3. Profitability by Market Segments

            14.1.4.4. Sales Footprint

            14.1.4.5. Strategy Overview

                14.1.4.5.1. Marketing Strategy

        14.1.5. Johnson & Johnson

            14.1.5.1. Overview

            14.1.5.2. Product Portfolio

            14.1.5.3. Profitability by Market Segments

            14.1.5.4. Sales Footprint

            14.1.5.5. Strategy Overview

                14.1.5.5.1. Marketing Strategy

        14.1.6. Astellas Pharma Inc.

            14.1.6.1. Overview

            14.1.6.2. Product Portfolio

            14.1.6.3. Profitability by Market Segments

            14.1.6.4. Sales Footprint

            14.1.6.5. Strategy Overview

                14.1.6.5.1. Marketing Strategy

        14.1.7. Bristol Myers Squibb

            14.1.7.1. Overview

            14.1.7.2. Product Portfolio

            14.1.7.3. Profitability by Market Segments

            14.1.7.4. Sales Footprint

            14.1.7.5. Strategy Overview

                14.1.7.5.1. Marketing Strategy

        14.1.8. Gedeon Richter Plc.

            14.1.8.1. Overview

            14.1.8.2. Product Portfolio

            14.1.8.3. Profitability by Market Segments

            14.1.8.4. Sales Footprint

            14.1.8.5. Strategy Overview

                14.1.8.5.1. Marketing Strategy

        14.1.9. H. Lundbeck A/S

            14.1.9.1. Overview

            14.1.9.2. Product Portfolio

            14.1.9.3. Profitability by Market Segments

            14.1.9.4. Sales Footprint

            14.1.9.5. Strategy Overview

                14.1.9.5.1. Marketing Strategy

        14.1.10. Pfizer Inc.

            14.1.10.1. Overview

            14.1.10.2. Product Portfolio

            14.1.10.3. Profitability by Market Segments

            14.1.10.4. Sales Footprint

            14.1.10.5. Strategy Overview

                14.1.10.5.1. Marketing Strategy

        14.1.11. Novartis AG

            14.1.11.1. Overview

            14.1.11.2. Product Portfolio

            14.1.11.3. Profitability by Market Segments

            14.1.11.4. Sales Footprint

            14.1.11.5. Strategy Overview

                14.1.11.5.1. Marketing Strategy

        14.1.12. Otsuka Holdings Co. Ltd

            14.1.12.1. Overview

            14.1.12.2. Product Portfolio

            14.1.12.3. Profitability by Market Segments

            14.1.12.4. Sales Footprint

            14.1.12.5. Strategy Overview

                14.1.12.5.1. Marketing Strategy

        14.1.13. Validus Pharmaceuticals LLC

            14.1.13.1. Overview

            14.1.13.2. Product Portfolio

            14.1.13.3. Profitability by Market Segments

            14.1.13.4. Sales Footprint

            14.1.13.5. Strategy Overview

                14.1.13.5.1. Marketing Strategy

15. Assumptions & Acronyms Used

16. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Forecast by Region, 2017-2032

Table 2: Global Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 3: North America Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 4: North America Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 5: Latin America Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 6: Latin America Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 7: Europe Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 8: Europe Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 9: Asia Pacific Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 10: Asia Pacific Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 11: Middle East and Africa Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 12: Middle East and Africa Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst
List of Charts

Figure 1: Global Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 2: Global Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) by Region, 2022-2032

Figure 3: Global Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Analysis by Region, 2017-2032

Figure 4: Global Bipolar Disorder Drugs and Treatment Market Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 5: Global Bipolar Disorder Drugs and Treatment Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 6: Global Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 7: Global Bipolar Disorder Drugs and Treatment Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 8: Global Bipolar Disorder Drugs and Treatment Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 9: Global Bipolar Disorder Drugs and Treatment Market Attractiveness by Drug Class, 2022-2032

Figure 10: Global Bipolar Disorder Drugs and Treatment Market Attractiveness by Region, 2022-2032

Figure 11: North America Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 12: North America Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) by Country, 2022-2032

Figure 13: North America Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 14: North America Bipolar Disorder Drugs and Treatment Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 15: North America Bipolar Disorder Drugs and Treatment Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 16: North America Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 17: North America Bipolar Disorder Drugs and Treatment Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 18: North America Bipolar Disorder Drugs and Treatment Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 19: North America Bipolar Disorder Drugs and Treatment Market Attractiveness by Drug Class, 2022-2032

Figure 20: North America Bipolar Disorder Drugs and Treatment Market Attractiveness by Country, 2022-2032

Figure 21: Latin America Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 22: Latin America Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) by Country, 2022-2032

Figure 23: Latin America Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 24: Latin America Bipolar Disorder Drugs and Treatment Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 25: Latin America Bipolar Disorder Drugs and Treatment Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 26: Latin America Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 27: Latin America Bipolar Disorder Drugs and Treatment Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 28: Latin America Bipolar Disorder Drugs and Treatment Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 29: Latin America Bipolar Disorder Drugs and Treatment Market Attractiveness by Drug Class, 2022-2032

Figure 30: Latin America Bipolar Disorder Drugs and Treatment Market Attractiveness by Country, 2022-2032

Figure 31: Europe Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 32: Europe Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) by Country, 2022-2032

Figure 33: Europe Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 34: Europe Bipolar Disorder Drugs and Treatment Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 35: Europe Bipolar Disorder Drugs and Treatment Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 36: Europe Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 37: Europe Bipolar Disorder Drugs and Treatment Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 38: Europe Bipolar Disorder Drugs and Treatment Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 39: Europe Bipolar Disorder Drugs and Treatment Market Attractiveness by Drug Class, 2022-2032

Figure 40: Europe Bipolar Disorder Drugs and Treatment Market Attractiveness by Country, 2022-2032

Figure 41: Asia Pacific Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 42: Asia Pacific Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) by Country, 2022-2032

Figure 43: Asia Pacific Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 44: Asia Pacific Bipolar Disorder Drugs and Treatment Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 45: Asia Pacific Bipolar Disorder Drugs and Treatment Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 46: Asia Pacific Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 47: Asia Pacific Bipolar Disorder Drugs and Treatment Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 48: Asia Pacific Bipolar Disorder Drugs and Treatment Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 49: Asia Pacific Bipolar Disorder Drugs and Treatment Market Attractiveness by Drug Class, 2022-2032

Figure 50: Asia Pacific Bipolar Disorder Drugs and Treatment Market Attractiveness by Country, 2022-2032

Figure 51: Middle East and Africa Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 52: Middle East and Africa Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) by Country, 2022-2032

Figure 53: Middle East and Africa Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 54: Middle East and Africa Bipolar Disorder Drugs and Treatment Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 55: Middle East and Africa Bipolar Disorder Drugs and Treatment Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 56: Middle East and Africa Bipolar Disorder Drugs and Treatment Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 57: Middle East and Africa Bipolar Disorder Drugs and Treatment Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 58: Middle East and Africa Bipolar Disorder Drugs and Treatment Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 59: Middle East and Africa Bipolar Disorder Drugs and Treatment Market Attractiveness by Drug Class, 2022-2032

Figure 60: Middle East and Africa Bipolar Disorder Drugs and Treatment Market Attractiveness by Country, 2022-2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate

Bipolar Disorder Drugs and Treatment Market